TORONTO, July 8, 2026
Conavi Medical Corp. announced the publication of a clinical case report in the Journal of the Society for Cardiovascular Angiography & Interventions (JSCAI) demonstrating the clinical utility of its hybrid intravascular ultrasound (IVUS) and optical coherence tomography (OCT) imaging system during a complex coronary intervention. The publication, titled “Versatility of Hybrid OCT and IVUS Imaging Enhances Contrast-Sparing Management of Eruptive Calcified Nodules,” describes how the company’s FDA 510(k)-cleared hybrid imaging platform provided complementary imaging information that supported lesion assessment, procedural planning, and stent optimization while minimizing contrast exposure in a patient with impaired renal function. The report further strengthens the growing body of clinical evidence supporting Conavi’s next-generation imaging technology as the company advances commercial deployment following its recent U.S. regulatory clearance.
Hybrid IVUS-OCT Imaging Improves Lesion Assessment and Treatment Planning
The published case demonstrates how combining IVUS and OCT within a single co-registered imaging platform allows physicians to utilize the strengths of both technologies throughout a percutaneous coronary intervention (PCI). During the procedure, clinicians employed high-resolution OCT imaging to clearly visualize thrombus formation over a calcified coronary nodule while using IVUS to evaluate vessel dimensions, characterize calcium distribution, and assess lesion morphology. The hybrid system enabled operators to seamlessly switch between combined imaging and IVUS-only imaging depending on clinical requirements, allowing physicians to obtain comprehensive anatomical information while reducing unnecessary contrast administration. According to the publication’s authors, this flexibility helped optimize treatment decisions and provided a more complete understanding of complex coronary lesions than either imaging modality alone could deliver independently.
Contrast-Sparing Approach Benefits Patients with Impaired Kidney Function
A major advantage highlighted in the publication was the ability of Conavi’s hybrid imaging system to support contrast-sparing coronary interventions, particularly for patients with compromised renal function who face increased risks from contrast-induced kidney injury. The clinicians selectively used OCT when its superior image resolution was essential for detailed visualization while relying primarily on IVUS-only imaging during other stages of the intervention to minimize contrast exposure. This adaptive imaging strategy allowed physicians to evaluate calcium burden, thrombus, vessel size, and final stent deployment while reducing reliance on repeated contrast injections. The study authors concluded that hybrid IVUS-OCT imaging may provide significant clinical value in patients with challenging plaque morphology, especially those with chronic kidney disease, where balancing image quality and patient safety is particularly important.
Advertisement
Clinical Evidence Supports Commercial Expansion Following FDA Clearance
The JSCAI publication represents another important milestone for Conavi Medical as it continues building clinical evidence supporting the adoption of its hybrid IVUS-OCT imaging system, which received U.S. FDA 510(k) clearance earlier in 2026. The company’s patented platform is the first imaging system capable of simultaneously co-registering and co-aligning intravascular ultrasound and optical coherence tomography within a single catheter, enabling physicians to access complementary imaging information during minimally invasive cardiovascular procedures. By combining enhanced lesion visualization, improved procedural flexibility, and reduced contrast exposure, the technology is designed to support more informed treatment decisions, optimize coronary stent placement, and improve patient outcomes. As commercialization expands, Conavi continues positioning its hybrid imaging platform as an advanced solution for image-guided cardiovascular interventions, particularly in complex coronary artery disease where comprehensive intravascular imaging can significantly influence procedural success.
Source: Conavi Medical press release
